Pharma, Prices and Power

Zusatztext

<p class="MsoNormal"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: #1000;">This book brings a negotiation perspective to healthcare. It opens the hidden box of pricing and reimbursement (P&R) negotiations, showing their huge impact on global healthcare systems and how they could be drastically improved.</span></p> <p class="MsoNormal"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: #1000;">The authors offer a comprehensive and unique negotiation-based analysis of healthcare systems worldwide, highlighting the historical, structural, and ethical challenges that shape P&R negotiations. From the role of governments and health insurers to the intricate dynamics between healthcare providers and users, the authors examine the forces driving healthcare costs and access. With a unique blend of theoretical expertise and practical experience, the authors propose a paradigm shift toward value-oriented negotiations. They show how to move away from adversarial win-lose tactics to collaborative and transparent negotiations.</span></p> <p class="MsoNormal"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: #1000;">Praise for the book</span><em><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: #1000;">:</span></em></p> <p style="line-height: 13.8pt; background: white; margin: 0cm 0cm 8.0pt 0cm;"><span style="color: black;"><em>I ran dozens of negotiations with health authorities and payors in Italy, France, Spain, Portugal, Germany and England, and the implementation of concepts developed by the authors such as (&hellip;) made it possible to radically change the dynamic of those negotiations, unlocking many complex reimbursement discussions and bringing innovative health solutions to patients across Europe.</em> <strong>&ndash; Valentino Confalone, Presidente Novartis Italia</strong></span></p> <p class="MsoNormal" style="margin-bottom: 8.0pt; line-height: 13.8pt;"><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; color: black;"><em>A must-read for anyone seeking to better understand the complexities of healthcare systems and the multiple perspectives present. On a foundation of win-win negotiation excellence the authors are leading us through dilemmas and trade-offs before finally leaving us equipped and inspired to collaboratively drive greater value in healthcare.</em> <strong>&ndash;</strong> <strong>Caroline Kaas Kristiansen, Head of Global Market Access Network & Excellence at Novo Nordisk</strong></span></p> <p class="MsoNormal"><span style="color: black;"> <em>T</em></span><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin;"><span style="color: black;"><em>his book offers valuable guidance for navigating this minefield. Through systematic analysis and practical approaches, it charts a path toward a common goal: enabling access to meaningful innovation that improves medical diagnosis and therapy, while preserving a profitable environment capable of delivering the medicines we need. Such guidance is both timely and essential.</em> <strong> &ndash; From the foreword by Dr Otmar Kloiber, Secretary General of the World Medical Association </strong></span></span></p> <p class="MsoNormal" style="margin-bottom: 8.0pt; line-height: 13.8pt;"><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin;"> </span><em><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; color: black;">This is a crucial resource for those engaged in pharmaceutical negotiations, providing a comprehensive view that reflects the complexity and significance of the process.(</span></em><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin;"><em>&hellip;</em><span style="color: black;"><em>). Highly recommended!</em> <strong>&ndash; Catarina Costa, Market Access and Public Affairs Professional at Novo Nordisk, formerly Pharmaceutical Technician at INFARMED (the Portuguese Medicine Agency)</strong></span></span></p> <p class="MsoNormal" style="margin-bottom: 8.0pt; line-height: 13.8pt;"><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin;"> </span><em><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; color: black;">I really enjoyed this book. (</span></em><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin;"><em>&hellip;<span style="color: black;">) It explained the challenges behind government and biopharma, and also the challenges in P&R negotiation. (</span>&hellip;<span style="color: black;">) In the execution level, this book even gives some vivid step-by-step examples on how to do a P&R negotiation. (</span>&hellip;</em><span style="color: black;"><em>) It gave me another angle to understand this toughest type of negotiation.</em> <strong>&ndash; Jessie Sijing Xiong, Strategy and Investment Director of WuXi Biologics</strong></span></span></p> <p class="MsoNormal"><span style="color: black;"> </span><em><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; color: black;">Pharma, Prices and Power </span><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; color: black;">is a must-read and a very meaningful and insightful contribution to helping stakeholders find better ways of working together. (</span></em><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin;"><em>&hellip;</em><span style="color: black;"><em>) The authors share great insights about the role that negotiations can play in navigating complex sets of incentives in healthcare and in identifying innovative ways to share information and interact differently to improve health value creation. </em> <strong>&ndash; Stephen Chick, Professor and Academic Director, INSEAD Healthcare Management Initiative</strong></span></span></p> <p class="MsoNormal" style="margin-bottom: 8.0pt; line-height: 13.8pt;"><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin;"> </span><span style="mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; color: black;"><em>The analyses made by the authors are intriguing and fundamental for us to have better days in health systems. (&hellip;) Like me, everyone who reads this book will be delighted and will get to know this pharmaceutical market even more. Congratulations to the authors, and thank you very much for providing us with this excellent masterpiece.</em> <strong>&ndash; Florentino Cardoso, Oncological Surgeon and President of the Brazilian Medical Association (2011-2017)</strong></span></p> <p class="MsoNormal"> </p>

Autorenportrait

<p class="MsoNormal"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: #1000;">Horacio Falcão created <em>Value Negotiation: How to Finally Get the Win-Win Right. </em>Horacio won the Best Elective Professor </span><span lang="EN-US" style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;">of the Year </span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: #1000;">at INSEAD </span><span lang="EN-US" style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;">21 times</span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: #1000;">, co-founded Value Negotiation (negotiation advisory), VN Tech (Negotiation SaaS), Qinect (AI in negotiation), and the INSEAD Negotiation and Conflict Management Collaborative.</span></p> <p class="MsoNormal"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: #1000;">Rodrigo Gouveia is a Partner at Value Negotiation, teaching Negotiation at INSEAD as </span><span lang="EN-US" style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;">a </span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; mso-ansi-language: #1000;">visiting professor. Since 2013, Rodrigo has helped strategize and support negotiations for over a dozen pharmaceutical products across 25 countries and has taught Market Access Win-Win negotiation to more than 500 people in the pharmaceutical industry.</span></p> <p><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin; color: black; background: white; mso-ansi-language: #1000; mso-fareast-language: EN-IN; mso-bidi-language: AR-SA;">Hervé Lamarque is a seasoned biopharma executive with leadership experience at companies including AstraZeneca, Bristol Myers Squibb, and Incyte Biosciences. He brings specific expertise in Pricing and Market Access strategy. Over the past 20 years, Hervé has led or participated in Market Access and pricing negotiations for more than 20 pharmaceutical products, with a track record of over 250 negotiations across more than 25 countries worldwide.</span></p>

Weitere Details